目的：探讨疏肝解郁胶囊治疗女性轻中度抑郁症患者的疗效和安全性。方法将60例女性轻中度抑郁症患者按随机数字表法分为两组，研究组口服疏肝解郁胶囊治疗，对照组口服帕罗西汀治疗，观察8周。治疗前后采用汉密顿抑郁量表、抑郁自评量表评定临床疗效，副反应量表评定不良反应。结果治疗1周末起两组汉密顿抑郁量表、抑郁自评量表评分均较治疗前显著下降（P＜0．01），研究组治疗2周、4周、6周、8周末评分显著低于对照组（P＜0．05或0．01）；治疗8周末研究组总有效率为93．33％，对照组为70．0％，研究组显著高于对照组（ P＜0．05）。研究组不良反应发生率为13．3％、对照组为40．0％，研究组显著低于对照组（ P＜0．01）。结论疏肝解郁胶囊治疗女性轻中度抑郁症起效快，疗效显著，安全性高。“,”Objective To explore the efficacy and safety of Shugan Jieyu capsule in mild to moderate fe‐male depression .Methods Sixty female patients with mild‐to‐moderate depression were divided into two groups according to random number table ,research group took orally Shugan Jieyu capsule ,and control group did paroxetine for 8 weeks .Efficacies were assessed with the Hamilton Depression Scale (HAMD) and Self‐rating Depression Scale (SDS) before and after treatment and adverse reactions with the Treat‐ment Emergent Symptom Scale (TESS) .Results Since the end of the 1st week the HAMD and SDS scores of both groups lowered significantly (P<0 .01) ,those were significantly lower in research than in control group at the ends of the 2nd ,4th ,6th and 8th week (P<0 .05 or 0 .01);at the end of the 8th week total effec‐tive rates were respectively 90 .0% in research and 70 .0% in control group ,the former significantly higher than the latter (P<0 .05);incidences of adverse reactions were respectively 13 .3% in research and 40 .0%in control group ,the former significantly lowerr than the latter (P<0 .01) .Conclusion Shugan Jieyucap‐sule takes effect more rapidly and has an evident effect and higher safety in female mild to moderate depression .